News
2010 | 2009 | 2008 | 2007 | 2006
London, 21 December 2006
ImmuPharma raises €7 million to advance programmes
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announced today that it has successfully raised just over €7 million (£4.71m) through the issue of new shares and an interest free unsecured Bond with warrants.
London, 30 October 2006
ImmuPharma announces further data from its IPP- 201101 phase II Lupus trial showing significant clinical improvement in patients
ImmuPharma plc (LSE:IMM), the specialist drug discovery and development company, announced today further data from its phase II trial with IPP-201101 for Lupus. Patients who received IPP-201101 on only 3 occasions, 2 weeks apart, demonstrated a significant clinical improvement in their condition in addition to the decrease of their biomarkers.
London, 17 October 2006
ImmuPharma announces highly positive preliminary Phase II results for its potential blockbuster treatment for Lupus
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announced today that its potential blockbuster IPP-201101 for Lupus treatment has met its Phase II primary endpoints.
London, 2 October 2006
ImmuPharma Announces Summary of Meeting with FDA for design of development programme for IPP-201101 treatment for Lupus
- Feedback reinforces model for potential fast track approval -
ImmuPharma plc (LSE:IMM), the specialist drug discovery and development company, announced today that it held a meeting with the United States Food and Drug Administration (“FDA”) on its IPP-201101 treatment for Lupus, a chronic, life-threatening autoimmune disease.
The meeting was held following the successful completion of the phase I trial of IPP-201101 and the initiation of the phase II trial, results of which are due to be announced before year-end. The purpose of the meeting was to discuss technical and scientific information and the proposed clinical protocol design for IPP-201101.
London, 26 SEPTEMBER 2006
IMMUPHARMA PLC
INTERIM RESULTS ANNOUNCEMENT
for the the three months ended 30th June 2006
ImmuPharma plc (LSE:IMM), (the "Company" or the "Group"), the specialist
pharmaceutical discovery and development Company is pleased to announce its
interim results for the three months ended 30th June 2006.
The interim figures are for three months due to the accounting reference
date of the Company year end being changed from 31st March to 31st
December, as highlighted in the full year statement issued on 1st August
2006.
London, 1 August 2006
IMMUPHARMA PLC
PRELIMINARY RESULTS
for the period ended 31 March 2006
ImmuPharma plc (LSE:IMM), the specialist pharmaceutical discovery and
development company is pleased to announce its preliminary results for the
period ended 31 March 2006.
Key Highlights:
• Successful placing and admission to AIM through reverse take over
in February 2006
• Received €1m in European Grant Funding from prestigious French
innovation agency in April 2006
• Successful completion of Phase I trial of our lead compound
IPP-201101, for the treatment of Lupus
• Phase II trials commenced in June 2006
London, 5 July 2006
ImmuPharma IPP- 201101 treatment for Lupus enters Phase II
- First patients dosed -
- Results expected before end of 2006 -
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announced today that its IPP-201101 treatment for Lupus, a chronic, life-threatening autoimmune disease, has entered into Phase II clinical trials. The first group of Lupus patients in the study have already been given the drug.
This European Phase II study in Lupus patients is a proof of concept, dose ranging, safety and efficacy study. The efficacy will be assessed using appropriate surrogate markers that are involved in the disease and biomarkers related to mechanism of action of IPP-201101. Results from this short duration study, expected by year end, will be of great value in preparation of pivotal Phase III studies.
London, 10 May 2006
ImmuPharma announces successful results from its phase I clinical trial with IPP-201101 for Lupus
- Phase II to start soon -
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development
company, announced today that it has successfully completed the
placebo-controlled phase I study involving 24 healthy volunteers of its
lead compound IPP-201101 for Lupus, a chronic, life-threatening autoimmune
disease.
This study, which took place in France, was the first administration in
humans for IPP-201101 and was designed to assess its safety and
tolerability. The preliminary safety report confirmed that the drug was
safe and well-tolerated.
London, 11 April 2006
ImmuPharma commences drawdown of prestigious research grants exceeding €1m
ImmuPharma PLC (LSE:IMM), the specialist pharmaceutical discovery and development company, announced today that it has started drawing down independent grants to assist with the development of its lead drug candidates. The grants which were approved in principle at the time of ImmuPharma's AIM admission in February 2006,have been awarded by ANVAR and ANR, two French state organisations that support innovative and promising R&D programmes.
London, 23 January 2006
Breakthrough drugs group ImmuPharma joins AIM
ImmuPharma plc, a drug discovery and development company focusing on the treatment of serious medical conditions such as Lupus, cancer pain and MRSA, is seeking admission to AIM.
London, 23 January 2006
Announcement from the London Stock Exchange
General Industries PLC
Proposed Reverse Takeover of ImmuPharma
Proposals for the acquisition of ImmuPharma, waiver of obligation under Rule 9 of the Takeover Code, Placing of new Shares for cash, change of directors and advisers and change of the Company's name to ImmuPharma plc
London, 15 February 2006
Announcement from the London Stock Exchange
General Industries PLC
Result of EGM and Placing
Reverse Takeover of ImmuPharma approved
At the Extraordinary General Meeting of General Industries PLC ("GI" or "the Company") held today all the resolutions were passed. These approved the acquisition of ImmuPharma PLC ("ImmuPharma"), an increase in the authorised share capital and powers of allotment; and the change of General Industries PLC's name to ImmuPharma PLC.
